Private Market View

TibaRay

Fremont, CA · Founded 2014 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$1.3M
Last round
Debt
Mar 2025

Key facts

  • It has raised $1.3M across 1 recorded rounds; the latest was Equity Crowdfunding ($10K) in Feb 2026.
  • Notable investors include U.S. Department of Energy, StartX (US), Keiretsu Forum, IHH Healthcare, K2X6 tracked in total.
  • TibaRay has filed 1 Form D with the SEC, most recently May 2025 ($1.3M sold to 10 investors).
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·Post-money valuations for all 1 rounds
  • ·The complete investor list — 6 names
  • ·Watchlist + deal alerts for TibaRay
Create free account
No card required

Funding rounds

1 rounds
Mar 2025Debt$1.3MSEC filing

About TibaRay

Developer of healthcare devices designed to create technologies to cure patients with all types and stages of cancer. The company offers radiation therapy, motion-freezing precision, conformal photons, CT imaging, and accelerators, enabling healthcare industries with novel linear accelerators, RF sources, and components.

Sector
Healthcare
HQ
Fremont, CA, United States
Founded
2014
Employees
16
Ownership
Privately Held (backing)
PA Mark — not yet priced

TibaRay doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in TibaRay shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on TibaRay in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.